Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model

• DOI: 10.1538/expanim.20-0103
• Publication Date: 2020-11-25T22:05:53Z
• Authors: Baran Akagunduz; Muhammet Ozer; Fatih Ozcıcek; Ali Veysel Kara; Sahin Lacın; Mustafa Özkaraca; Abdulkadir Çoban; Bahadır Suleyman; Renad Mammadov; Halis Suleyman
• Keywords: Pazopanib; Taxifolin

Pazopanib is a tyrosine kinase inhibitor that generally used for the treatment of metastatic renal cell cancer and advanced soft tissue sarcoma. It can cause various degrees hepatotoxicity. Our study aimed to investigate effect taxifolin on pazopanib-induced liver toxicity. A total 18 rats were divided into three groups: pazopanib (PP), plus (TPP), control (C) group. Taxifolin was administered TPP (n=6) group with dose 50 mg/kg. Distilled water orally admnistered C PP groups as solvent. Subsequently, 200 mg/kg via stomach. This procedure repeated once day four weeks. Then, all sacrificed, their livers removed. Malondialdehyde (MDA), glutathione (tGSH), oxidant status (TOS), antioxidant (TAS) levels evaluated. MDA TOS higher in compared other parameters (P<0.001). tGSH TAS lower than (P<0.001), aspartate aminotransferase (AST), alanine (ALT), lactate dehydrogenase (LDH) higher. Furthermore, damage, including hemorrhage, hydropic degeneration, necrosis observed Administration before significantly improved degenerative changes. demonstrated administration effective preventing hepatotoxicity rats.